Abstract
Eribulin is a novel antimicrotubule drug, which is approved in the second line treatment of advanced breast cancer in patients who received anthracyclines and taxanes. The article presents the results of two huge phase III clinical trials (301, 305) and their pooled analysis. Eribulin monotherapy demonstates staistically significant improved overall survival compared to standart treatments (15.2 mnths vs 12.8 mnths, p = 0.03 in pooled analysis). Certain subgroups of patients--Her2-negative and triple-negative have the most survival benefit. According to own experience with Eribulin inside the clinical trials, presented in the article, the drug is effective and well tolerated even by older patients.
Publication types
-
Clinical Trial, Phase III
-
Randomized Controlled Trial
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / mortality
-
Breast Neoplasms / pathology*
-
Drug Administration Schedule
-
Female
-
Furans / administration & dosage
-
Furans / adverse effects
-
Furans / therapeutic use*
-
Humans
-
Kaplan-Meier Estimate
-
Ketones / administration & dosage
-
Ketones / adverse effects
-
Ketones / therapeutic use*
-
Leukopenia / chemically induced
-
Meta-Analysis as Topic
-
Microtubules / drug effects*
-
Neutropenia / chemically induced
-
Severity of Illness Index
-
Treatment Outcome
-
Triple Negative Breast Neoplasms / drug therapy
Substances
-
Antineoplastic Agents
-
Furans
-
Ketones
-
eribulin